Muhammad Yasin Selected Research

Muhammad Yasin Research Topics

2	Infections 01/2024 - 10/2018
2	Cognitive Dysfunction 11/2023 - 08/2022
2	Coronary Artery Disease (Coronary Atherosclerosis) 04/2008 - 11/2003
2	Coronary Disease (Coronary Heart Disease) 04/2008 - 11/2003
2	Atherosclerosis 04/2008 - 11/2003
1	Neoplasms (Cancer) 12/2023
1	Neurodegenerative Diseases (Neurodegenerative Disease) 12/2023
1	Inflammation (Inflammations) 01/2023
1	Intellectual Disability (Idiocy) 01/2023
1	Dehydration (Water Stress) 10/2022
1	Pericardial Effusion 11/2018
1	Atrioventricular Block 11/2018
1	Type 2 Diabetes Mellitus (MODY) 10/2018
1	Osteomyelitis 10/2018
1	Ulcer 10/2018
1	Heart Failure 01/2018
1	Weight Gain 07/2011
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2008
1	Disease Progression 04/2008
1	Body Weight (Weight, Body) 04/2008
1	Weight Loss (Weight Reduction) 04/2008
1	Abdominal Obesity 04/2008
1	Acute Coronary Syndrome 11/2003
1	Atherosclerotic Plaque (Atheroma) 11/2003

2	MelatoninIBA 01/2024 - 12/2023
1	Melatonin Receptors (Melatonin Receptor)IBA 12/2023
1	Anaphase-Promoting Complex-Cyclosome Apc2 SubunitIBA 11/2023
1	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 01/2023
1	LipoxygenasesIBA 01/2023
1	5' Untranslated Regions (5' UTR)IBA 01/2023
1	EnzymesIBA 01/2023
1	Butanols (Butyl Alcohols)IBA 10/2022
1	Deep Eutectic SolventsIBA 10/2022
1	1-Butanol (n Butanol)IBA 10/2022
1	NF-kappa B (NF-kB)IBA 08/2022
1	DNA (Deoxyribonucleic Acid)IBA 08/2022
1	Minoxidil (Rogaine)FDA LinkGeneric 11/2018
1	Paliperidone Palmitate FDA Link 11/2018
1	Anti-Bacterial Agents (Antibiotics)IBA 10/2018
1	Tazobactam Drug Combination Piperacillin (Zosyn)FDA LinkGeneric 10/2018
1	Thiobarbituric Acid Reactive SubstancesIBA 07/2011
1	RimonabantIBA 04/2008
1	CannabinoidsIBA 04/2008
1	HDL CholesterolIBA 11/2003
1	Phospholipids (Phosphatides)FDA LinkGeneric 11/2003
1	ETC216IBA 11/2003
1	Apolipoprotein A-I (Apolipoprotein A1)IBA 11/2003

1	Length of Stay 10/2018
1	Surgical Amputation (Amputations) 10/2018
1	Stents 01/2018
1	Obesity Management 04/2008